Professional and Scientific Grants

Shionogi Inc. as of March 10, 2017 is no longer marketing Osphena and has transferred the asset to Duchesnay Inc. Shionogi Inc. at this time will no longer support research initiatives, grants or congress support related to Women’s Health. If you would like to engage with Duchesnay regarding the Osphena brand, you may contact Carole Boyer, VP of Corporate Affairs at:

We sincerely thank you for your past interest and support of Osphena used for the treatment of Dyspareunia due to menopause.

For Opioid induced constipation (OIC), Shionogi Inc. has entered into a collaboration with Purdue Pharma and unsolicited grant requests for OIC should be submitted directly to Purdue Pharma at .